GLP-1 Real-World Weight Loss Data (2026): How Patients Actually Compare to Clinical Trials

Updated June 2026 · Reviewed by the MealFan editorial team

Published: June 12, 2026|Written by: Eric Sornoso, Founder and Lead Reviewer|Data sources: Truveta, Epic Cosmos, Komodo Health, peer-reviewed trials.

Key finding: Real-world GLP-1 patients lose substantially less weight than clinical trial subjects. Wegovy patients in 2024 to 2025 real-world studies averaged 9.1 percent weight loss at 12 months vs 14.9 percent in the STEP 1 trial. Zepbound real-world averages 12.4 percent vs 20.9 percent in SURMOUNT 1. The 5 to 8 percentage point gap is driven by lower adherence, faster discontinuation, and slower dose escalation outside controlled trials.

Not medical advice. Original analysis of published real-world evidence studies and pharmaceutical industry data.

Key takeaways

Real-world weight loss usually trails trial averages.
Whatever the number, too little protein turns fat loss into muscle loss.
Target 1.2 to 1.6 g protein per kg daily plus resistance activity.
Nutrient density matters more as total intake drops.

The MealFan angle (what the drug sites skip): on GLP-1 medications, your appetite can drop 30 to 60%, so the danger shifts from eating too much to under-eating protein and losing muscle. Protecting muscle and covering micronutrients matters as much as the medication itself. Jump to the nutrition plan ↓ or see our tested GLP-1 meal delivery picks.

Get your free personalized GLP-1 planYour protein target, food picks and a reader offer

›

Free 0b7 takes 10 seconds 0b7 no spam

Weight

Units

Height (ft)

Height (in)

Age

Sex

Diet

Where should we send your plan?

Your exact daily protein and calorie target
Protein foods that fit your diet and allergies
50% off your first CookUnity box

Please enter a valid email.

Your plan and offer are emailed instantly. No spam, unsubscribe anytime, and we never sell your data.

Clinical trial vs real-world weight loss outcomes

Medication	Clinical trial loss at 12mo	Real-world loss at 12mo	Gap	Source
Wegovy 2.4mg (semaglutide)	14.9% (STEP 1)	9.1%	-5.8pp	Gleason et al, Truveta 2024 (n=7,881)
Ozempic 1.0mg (semaglutide T2D)	6.5kg (SUSTAIN 7)	4.2kg	-35%	Epic Cosmos 2024 (n=24,400)
Zepbound 15mg (tirzepatide)	20.9% (SURMOUNT 1)	12.4%	-8.5pp	Truveta tirzepatide cohort 2024 (n=3,624)
Mounjaro 15mg (T2D)	12.9kg (SURPASS 3)	8.7kg	-33%	Komodo Health 2024 (n=18,200)

What drives the trial vs real-world gap

Four factors account for almost the entire performance gap between clinical trial outcomes and real-world patient outcomes.

Factor	Clinical trial	Real world
12-month adherence rate	87 to 92%	32 to 42%
Reach maintenance dose	95%	58%
Discontinuation by month 12	8%	38 to 58%
Concurrent lifestyle counseling	Required (per protocol)	~15% receive any

Why patients quit GLP-1 medications

37%. Cost: Out-of-pocket pricing of $1,000-$1,800/month is the #1 reason.
28%. Side effects: Persistent nausea, GI issues, or fatigue.
18%. Reached goal weight: Often followed by regain (averaging 67% regain within 12 months of stopping per STEP 4 extension data).
12%. Insurance change: Lost coverage or formulary changed.
5%. Other: Including supply shortages 2022 to 2024.

Adherence correlates directly with weight loss outcomes

Real-world weight loss outcomes scale linearly with adherence. The Truveta 2024 Wegovy cohort segmented by adherence shows:

Patients with >80% adherence: 13.7% weight loss at 12mo (close to trial 14.9%)
Patients with 60 to 80% adherence: 10.4% weight loss
Patients with 40 to 60% adherence: 6.8% weight loss
Patients with

The 5.8 percentage point gap between real-world average (9.1%) and trial outcome (14.9%) is almost entirely explained by the difference in adherence between trial subjects (87 to 92%) and real-world patients (32 to 42%).

What helps close the gap

Three interventions show measurable real-world benefit in published 2024 to 2025 evidence:

Structured nutrition support: Patients enrolled in registered dietitian programs alongside GLP-1 medication achieve 11.8% weight loss vs 7.4% without (Komodo Health 2024 sub-analysis).
Meal delivery + GLP-1: Anecdotal but consistent in patient surveys. Factor and Trifecta both report 30%+ YoY growth in GLP-1 user segment 2024 to 2025.
Resistance training 2 to 3x/week: Reduces lean mass loss from 25 to 39% of total weight lost to 12 to 15% (multiple Lancet sub-analyses).

Implications for patients

If you are on a GLP-1 medication, the data say three things:

Plan for real-world outcomes, not trial outcomes. Realistic expectation: 8 to 12% body weight loss at 12 months on Wegovy, 11 to 14% on Zepbound. Anything above that is a bonus.
Adherence is the single biggest controllable factor. Missing weekly doses costs more weight loss than any food choice you can make.
Structured nutrition support matters. Either a dietitian or a structured meal delivery service narrows the trial-vs-real gap.

Sources and methodology

Real-world weight loss data synthesized from: Gleason et al, “Real-world semaglutide outcomes in commercially-insured adults” (Truveta 2024 publication, n=7,881); Epic Cosmos GLP-1 Outcomes Dashboard 2024 (n=24,400 Ozempic patients); Truveta tirzepatide cohort analysis 2024 (n=3,624 Zepbound patients); Komodo Health Mounjaro real-world evidence study 2024 (n=18,200). Clinical trial data from Wilding et al (STEP 1, NEJM 2021), Jastreboff et al (SURMOUNT 1, NEJM 2022), Pratley et al (SUSTAIN 7, Lancet 2018), Ludvik et al (SURPASS 3, Lancet 2021). Adherence and discontinuation data from IQVIA real-world drug utilization reports 2024.

How to cite this report

For journalists and researchers: cite as “MealFan, GLP-1 Real-World Weight Loss Data 2026, June 12, 2026” with a link to this page. All data tables are free to embed with attribution.

Related research and guides

GLP-1 statistics 2026: prescription growth, manufacturer revenue, demographics.
Best GLP 1 meal delivery: ranked services for Ozempic, Wegovy, Mounjaro, Zepbound users.
What to eat on Ozempic: practical daily food guide.
Best protein shakes for Ozempic: protein supplementation guide with brand pricing.

The nutrition side most drug guides skip

We are a food site, so here is what the drug-only sites leave out: GLP-1 medications works by shrinking appetite, and that creates a real nutritional risk. When you eat far less, you do not just lose fat, you can lose muscle and fall short on protein, fiber, and key vitamins and minerals. The fix is not eating more; it is making every bite count.

The four risks to manage (and the food fix)

Nutrition risk	Why it happens	The food fix
Muscle & protein loss	Rapid weight loss plus too little protein, up to a third of lost weight can be lean muscle.	1.2 to 1.6 g protein per kg body weight daily; protein at every meal and snack.
Low micronutrients	Eating far less total food shrinks intake of iron, B12, calcium, vitamin D, potassium and magnesium.	Nutrient-dense picks: eggs, salmon/sardines, Greek yogurt, leafy greens, beans, nuts and seeds.
Constipation	Slowed digestion plus less food and fiber.	Fiber-rich vegetables and fruit you tolerate; steady fluids; move daily.
Dehydration & low energy	Reduced intake and GI fluid losses.	Sip fluids and electrolytes through the day; never skip food entirely.

What to actually eat

Protein at every meal and snack: eggs, chicken, fish, Greek yogurt, cottage cheese, tofu, beans, or a protein shake.
Nutrient-dense, smaller-volume foods: salmon and sardines (omega-3, vitamin D, B12), eggs, dairy, leafy greens, beans and lentils, nuts and seeds, berries.
Easy formats for nausea days: protein smoothies, broth-based soups, yogurt.
Hydration and fiber: water and electrolytes plus tolerable high-fiber vegetables and fruit.

If your appetite is so low that you are eating very little, a daily multivitamin can backstop the gaps, ask your prescribing clinician.

The simplest way to hit these numbers while appetite is unpredictable is pre-portioned, macro-labeled meal delivery.

See our tested GLP-1 meal delivery picks →
Best High-Protein Meal Delivery

Sources & references

Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine (2021).
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine (2022).
Glucagon-like peptide-1 (GLP-1), mechanism and agonists. Wikipedia.

At a glance

More receptor pathways has tracked with more weight loss; real-world outcomes usually trail trial numbers.

The next-generation drug: retatrutide ("reta") showed ~24 to 28% weight loss in trials. Retatrutide guide · Retatrutide vs tirzepatide.

Frequently Asked Questions

How does real-world GLP-1 weight loss compare to clinical trials?

Real-world data generally shows 10-14% weight loss over 12 months, somewhat lower than the 15-22% seen in controlled trials, likely due to inconsistent adherence and dose titration outside clinical settings.

Do people regain weight after stopping GLP-1 medication?

Yes. Most studies show patients regain the majority of lost weight within 12-18 months of discontinuation, reinforcing that these medications work best as long-term treatment rather than short courses.

Which GLP-1 medication produces the most weight loss in real-world use?

Tirzepatide (Zepbound/Mounjaro) consistently shows higher weight loss in real-world studies compared to Semaglutide (Wegovy/Ozempic), with average losses of 15-18% vs. 10-13% over a year.

FREE · 5 QUESTIONS · ~2 MIN

Find your meal kit in 2 minutes

Answer 5 quick questions. We'll match you to the top 3 from 24 services we track.

Take the Quiz No signup · Just answers